Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of MRM-3379 in male participants with Fragile X syndrome
2025-523738-21-00Phase 2Authorised
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Fragile X syndrome (FXS) comparing MRM-3379 with Placebo (2 arms). Primary endpoints: Incidence and severity of treatment-emergent adverse events (TEAEs) and Withdrawal due to adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
DNS-3379
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on 2025-523738-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523738-21-00.